HomeAI · summaries
Storia in 6 fonti
Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic | Fortune
America's waistline may shrink, but its national debt will swell.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
forbes.com
Trump Says Obesity Drugmakers Will Cut GLP-1 Prices—Medicare Will Cover Some Costs
The deal also means Medicare will start covering obesity drugs for some patients for the first time beginning next year.
- ·
cnbc.com
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
The deals are among the most politically significant announcements to date in the Trump administration's efforts to rein in high U.S. drug costs.
- ·
bbc.com
Trump unveils deals to lower US weight-loss drug prices
US President Donald Trump announces agreements with drug makers Eli Lilly and Novo Nordisk.
- ·
fortune.com
Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic | Fortune
America's waistline may shrink, but its national debt will swell.
- ·
upi.com
Trump announces deal to lower prices for obesity drugs - UPI.com
Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare recipients and those who pay directly.
- ·
aljazeera.com
Weight-loss drug makers announce pricing agreement with Trump
The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients.
- ·
Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more private insurers to follow suit.
- ·
'Do you take any of this stuff, Howard?' Trump roasts his cabinet about their weight while announcing blockbuster Medicare Ozempic deal |…
"Obesity is a disease of poverty," HHS Secretary Robert Kennedy said, ignoring data that shows it's mainly a middle-class ailment.
- ·
Pfizer beats out Novo Nordisk in bidding for obesity drugmaker Metsera | Fortune
Metsera has no products on the market, but it is developing oral and injectable treatments.